Aspen Pharmacare – is the market rating the share price too low? Read the long-term Mergence houseview by Portfolio Manager Izak van Niekerk.
Absa CEO Arrie Rautenbach steps down as the group’s valuation continues to lag that of its peers
Commenting on Absa’s results and the surprise announcement of CEO Arrie Rautenbach stepping down, Mergence Senior Analyst Radebe Sipamla said